Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) serves as a notification to the U.S. Securities and Exchange Commission regarding the submission of its Annual Report on Form 20-F for the fiscal year ended December 31, 2014. The Form 20-F was filed on February 27, 2015, and contains audited financial statements. This specific Form 6-K was dated March 2, 2015.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Annual Report on Form 20-F, which is available on GSK's website and the SEC's EDGAR database.
Material Changes
The filing does not disclose specific material changes in financial performance or operations compared to prior periods. It solely announces the availability of the audited 2014 financial statements.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements. Management notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as being detailed in Item 3.D of the 2014 Annual Report on Form 20-F. No specific guidance or outlook figures are provided in this document.
Investor Verification Checklist
- Verify the availability and content of the Annual Report on Form 20-F filed on February 27, 2015, for detailed 2014 financial data.
- Review Item 3.D "Risk factors" in the Form 20-F for specific disclosures regarding uncertainties affecting future performance.
- Confirm the date of the Annual General Meeting and the availability of hard copy reports via the registrars (Equiniti) or ADR depositary (BNY Mellon).